MCID: PSY004
MIFTS: 68

Psychotic Disorder

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Psychotic Disorder

MalaCards integrated aliases for Psychotic Disorder:

Name: Psychotic Disorder 12 15
Psychotic Disorders 43 15 72
Mental or Behavioural Disorder 12 17
Mental Disorders 72
Psychotic 55

Classifications:

ICD10: 33


Summaries for Psychotic Disorder

MedlinePlus : 43 Psychotic disorders are severe mental disorders that cause abnormal thinking and perceptions. People with psychoses lose touch with reality. Two of the main symptoms are delusions and hallucinations. Delusions are false beliefs, such as thinking that someone is plotting against you or that the TV is sending you secret messages. Hallucinations are false perceptions, such as hearing, seeing, or feeling something that is not there. Schizophrenia is one type of psychotic disorder. People with bipolar disorder may also have psychotic symptoms. Other problems that can cause psychosis include alcohol and some drugs, brain tumors, brain infections, and stroke. Treatment depends on the cause of the psychosis. It might involve drugs to control symptoms and talk therapy. Hospitalization is an option for serious cases where a person might be dangerous to himself or others.

MalaCards based summary : Psychotic Disorder, also known as psychotic disorders, is related to schizophreniform disorder and delusional disorder, and has symptoms including photophobia, agitation and lethargy. An important gene associated with Psychotic Disorder is COMT (Catechol-O-Methyltransferase), and among its related pathways/superpathways are Circadian entrainment and Beta-Adrenergic Signaling. The drugs Reboxetine and Ferrous succinate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are no effect and behavior/neurological

Disease Ontology : 12 A cognitive disorder that involves abnormal thinking and perceptions resulting in a disconnection with reality.

Wikipedia : 75 Psychosis is an abnormal condition of the mind that results in difficulties determining what is real and... more...

Related Diseases for Psychotic Disorder

Diseases related to Psychotic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 661)
# Related Disease Score Top Affiliating Genes
1 schizophreniform disorder 33.9 PRL NRG1 DRD2 COMT
2 delusional disorder 33.1 DRD4 DRD3 DRD2
3 schizophrenia 2 32.8 DRD3 DISC1
4 schizoaffective disorder 31.6 SLC6A4 SLC1A1 PRODH PRL HTR2A DTNBP1
5 depression 31.5 SLC6A4 HTR2A BDNF
6 anxiety 31.4 SLC6A4 HTR2A COMT BDNF
7 mental depression 31.4 SLC6A4 HTR2A COMT BDNF
8 traumatic brain injury 31.1 DRD2 COMT BDNF
9 brain injury 31.1 DRD2 COMT BDNF
10 substance-induced psychosis 31.1 HTR2A DRD2
11 eating disorder 31.0 SLC6A4 DRD2 COMT BDNF
12 paranoid schizophrenia 31.0 SLC6A4 HTR2A COMT BDNF
13 tardive dyskinesia 31.0 HTR2A DRD3 DRD2 COMT
14 substance abuse 30.9 SLC6A4 PRL DRD4 DRD3 DRD2 COMT
15 endogenous depression 30.8 SLC6A4 HTR2A BDNF
16 borderline personality disorder 30.8 SLC6A4 HTR2A COMT BDNF
17 galactorrhea 30.8 PRL DRD2
18 antisocial personality disorder 30.8 SLC6A4 MAOB DRD2 COMT
19 generalized anxiety disorder 30.7 SLC6A4 HTR2A DRD2 COMT BDNF
20 drug dependence 30.7 SLC6A4 DRD3 DRD2 BDNF
21 tic disorder 30.7 HTR2A DRD4 DRD2
22 panic disorder 30.7 SLC6A4 HTR2A COMT
23 personality disorder 30.7 SLC6A4 PRL HTR2A DRD4 DRD2 COMT
24 polysubstance abuse 30.6 DRD3 DRD2 COMT
25 cocaine dependence 30.6 SLC6A4 DRD3 DRD2
26 autism spectrum disorder 30.6 SLC6A4 NRXN1 HTR2A BDNF
27 migraine with or without aura 1 30.6 SLC6A4 HTR2A DRD3 DRD2 COMT
28 post-traumatic stress disorder 30.6 SLC6A4 MAOB HTR2A DRD2 COMT BDNF
29 pervasive developmental disorder 30.5 SLC6A4 NRXN1 BDNF
30 alexithymia 30.5 SLC6A4 DRD2 COMT
31 chronic fatigue syndrome 30.5 SLC6A4 HTR2A COMT
32 opiate dependence 30.5 SLC6A4 DRD3 DRD2
33 schizophrenia 1 30.5 NRG1 DTNBP1 DISC1
34 postpartum depression 30.5 SLC6A4 PRL COMT BDNF
35 autism 30.5 SYN2 SLC6A4 NRXN1 HTR2A BDNF
36 social phobia 30.5 SLC6A4 PRL DRD2
37 cocaine abuse 30.4 SLC6A4 PRL DRD2
38 serotonin syndrome 30.4 SLC6A4 MAOB HTR2A
39 bulimia nervosa 30.4 SLC6A4 HTR2A COMT BDNF
40 mood disorder 30.4 SLC6A4 MAOB HTR2A DRD4 DRD3 DRD2
41 anorexia nervosa 30.4 SLC6A4 PRL HTR2A COMT BDNF
42 tobacco addiction 30.4 SLC6A4 NRXN1 HTR2A DRD2 COMT
43 alcoholic psychosis 30.4 SLC6A4 HTR2A DRD2
44 heroin dependence 30.4 DRD4 DRD2 BDNF
45 atypical depressive disorder 30.3 SLC6A4 MAOB HTR2A
46 early-onset schizophrenia 30.3 HTR2A DRD2 DRD1 BDNF
47 conduct disorder 30.3 SLC6A4 DRD4 DRD2 COMT
48 alcohol-induced mental disorder 30.2 SLC6A4 DRD2
49 fibromyalgia 30.2 SLC6A4 PRL HTR2A COMT
50 gilles de la tourette syndrome 30.2 DRD4 DRD2 COMT BDNF

Graphical network of the top 20 diseases related to Psychotic Disorder:



Diseases related to Psychotic Disorder

Symptoms & Phenotypes for Psychotic Disorder

UMLS symptoms related to Psychotic Disorder:


photophobia, agitation, lethargy, restlessness, personality changes, pseudobulbar behavioral symptoms, sleep disturbances, mental and behavioral signs and symptoms, forgetful, decrease in appetite, symptoms, nervousness, feeling jittery, alexithymia, increased libido, numbness, psychiatric symptom, hallucinations, auditory, hallucinations, visual, numbness localized, feeling detached, feeling strange, feeling weightless, floating feeling, dejection emotional, depressed reaction, hallucinations, sensory, restless sleep, difficulty sleeping, excitability, depression aggravated, agitation mental, numb mouth, opiate withdrawal symptoms, clouded consciousness, trembling inside, sluggishness, catatonic reaction

GenomeRNAi Phenotypes related to Psychotic Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 BDNF COMT DAO DAOA DISC1 DRD1

MGI Mouse Phenotypes related to Psychotic Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.28 BDNF COMT DAO DISC1 DRD1 DRD2
2 homeostasis/metabolism MP:0005376 10.16 BDNF COMT DAO DISC1 DRD1 DRD2
3 nervous system MP:0003631 9.89 BDNF COMT DAO DISC1 DRD1 DRD2
4 integument MP:0010771 9.76 BDNF DRD1 DRD2 DTNBP1 PRL PRODH
5 renal/urinary system MP:0005367 9.17 COMT DRD2 DRD3 DTNBP1 MAOB RGS4

Drugs & Therapeutics for Psychotic Disorder

Drugs for Psychotic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 668)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Reboxetine Approved, Experimental Phase 4 98769-81-4, 71620-89-8 123628 65856
2
Ferrous succinate Approved Phase 4 10030-90-7
3
Amlodipine Approved Phase 4 88150-42-9 2162
4
Atenolol Approved Phase 4 29122-68-7 2249
5
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
6
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
7
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
8
Cinnarizine Approved, Investigational Phase 4 298-57-7 1547484 2761
9
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
10
Zinc Approved, Investigational Phase 4 7440-66-6 32051
11
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
12
Cyproheptadine Approved Phase 4 129-03-3 2913
13
Trifluoperazine Approved, Investigational Phase 4 117-89-5 5566
14
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
15
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
16
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
17
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
18
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
19
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
20
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
21
Amitriptyline Approved Phase 4 50-48-6 2160
22
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
23
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
24
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
25
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
26
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
27
Pravastatin Approved Phase 4 81093-37-0 54687
28
Allopurinol Approved Phase 4 315-30-0 2094
29
Ondansetron Approved Phase 4 99614-02-5 4595
30
Pramlintide Approved, Investigational Phase 4 151126-32-8
31
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
32
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
33
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
34
Sodium citrate Approved, Investigational Phase 4 68-04-2
35
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 5195 26757
36
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
37
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
38
Allantoin Approved Phase 4 97-59-6 204
39
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
40
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
41
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
42
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
43
Insulin glargine Approved Phase 4 160337-95-1
44
Gliclazide Approved Phase 4 21187-98-4 3475
45
Nortriptyline Approved Phase 4 72-69-5 4543
46
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
47
Cyclizine Approved Phase 4 82-92-8 6726
48
Scopolamine Approved, Investigational Phase 4 6533-68-2, 51-34-3 5184
49
Bisoprolol Approved Phase 4 66722-44-9 2405
50
Clozapine Approved Phase 4 5786-21-0 2818

Interventional clinical trials:

(show top 50) (show all 2909)
# Name Status NCT ID Phase Drugs
1 An Open-label Switch Study to Asenapine in the Early Stage of Psychosis Unknown status NCT01968161 Phase 4 Asenapine
2 Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis- An Investigator-initiated, Phase IV, Randomised Double-blind Multi-centre Trial of the Benefits and Harms of Aripiprazole Versus Quetiapine in Children and Adolescents With Psychosis Unknown status NCT01119014 Phase 4 Aripiprazole;Quetiapine
3 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
4 Determining the Efficacy and Tolerance of Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry Unknown status NCT00986167 Phase 4 Quetiapine XR
5 Efficacy of Exposure and Response Prevention(ERP) and SSRIs, and Its Predictors in Obsessive-Compulsive Disorder Unknown status NCT02022709 Phase 4 Fluoxetine;Sertraline;Paroxetine;Citalopram;Fluvoxamine
6 A Double Blind Placebo Controlled Study of Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia Unknown status NCT00469664 Phase 4 Guanfacine/Tenex
7 Donepezil Double Blind Trial for ECT Memory Disfunction Unknown status NCT00465283 Phase 4 Donepezil
8 Identifying Predictors of Response in 12 Weeks of Treatment With Antipsychotics Using a Treatment Algorithm for Schizophrenia Unknown status NCT01016145 Phase 4 Antipsychotics;Antipsychotics
9 A Multi-Center,Open-Labeled,Intervention Study:The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation Unknown status NCT02935998 Phase 4 Ziprasidone
10 A Study on the Efficacy, Pharmacokinetics and Adverse Effects of Paliperidone ER Unknown status NCT02433717 Phase 4 Paliperidone ER
11 Phase 3 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study Unknown status NCT00426946 Phase 4 Reboxetine
12 Effectiveness of Long-Acting Risperidone in the Maintenance Treatment of First-Episode Schizophrenia Unknown status NCT00220714 Phase 4 atypical antipsychotics:oral vs. long-acting route
13 Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
14 Association of the Amisulpride Treatment Response in Patients With Schizophrenia With the Findings of Brain Structural Magnetic Resonance Imaging Unknown status NCT02095938 Phase 4 amisulpride
15 Locus Coeruleus Neuroimaging of Antipsychotic/Modafinil Interactions on Cognition in Schizophrenia Unknown status NCT01913327 Phase 4 Aripiprazole;Risperidone;Modafinil
16 Effect of Slow-release Melatonin (Circadin®) Therapy on Idiopathic REM Sleep Behavior Disorder: a Pilot Study Unknown status NCT02836743 Phase 4 Circadin;Placebo
17 Randomized, Controlled Study of Iron Supplementation of Infants With Birth Weights 2000-2500 g Unknown status NCT00558454 Phase 4 Iron
18 Identification and Treatment of the Liability to Develop Schizophrenia Unknown status NCT00305474 Phase 4 Risperidone
19 Phase IV Study of Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) Unknown status NCT01250847 Phase 4 Quetiapine(Seroquel-XR) 50~800mg a day
20 Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder Unknown status NCT02252341 Phase 4
21 A Randomized Controlled Trial of Antidepressant Maintenance for Major Depression Following Mild Traumatic Brain Injury Unknown status NCT00162916 Phase 4 citalopram;Placebo
22 Sequenced Therapies for Comorbid and Primary Insomnias Unknown status NCT01651442 Phase 4 Zolpidem;Trazodone
23 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients. Unknown status NCT01246310 Phase 4
24 Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
25 The Assessment of Efficacy and Tolerability of Methylphenidate vs. Risperidone in the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
26 Omega-3 Fatty Acids in First-episode Schizophrenia - a Randomized Controlled Study of Efficacy and Relapse Prevention (OFFER). Rationale, Design, and Methods. Unknown status NCT02210962 Phase 4
27 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder: a Randomized, Double Blind Clinical Trial. Unknown status NCT00437099 Phase 4 Omacor®;Placebo
28 The Effect of a Community-based Long-acting Antipsychotic-treated Management Model on the Violence Risk of Patients With Schizophrenia: a 1-year, Open-label Randomized Controlled Study Unknown status NCT03080194 Phase 4 paliperidone palmitate;control group
29 Effect of Subanesthetic Dose of Ketamine Combined With Propofol on Cognitive Function in Depressive Patients Undergoing Electroconvulsive Therapy ---a Randomized Control Double-Blind Clinical Trial Unknown status NCT02305394 Phase 4 ketamine and propofol;propofol and normal saline
30 The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
31 A Randomized Controlled Study of Nifecardia SRFC (Nifedipine) and Adalat OROS (Nifedipine) in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4 Nifedipine 30 mg GITS
32 Risperidone and Zotepine in the Treatment of Delirium Unknown status NCT00622011 Phase 4 Risperidone and Zolpidem for delirium
33 Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia Unknown status NCT00838032 Phase 4 Quetiapine fumarate;Haloperidol
34 Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial Unknown status NCT00813722 Phase 4 amlodipine (calcium chanel blocker) and losartan (at1 antagonist);atenolol (beta blocker) and hydrochlorothiazide (diuretic)
35 Frailty and Cognitive Function Assessment of TAVI Patients (The Hungarian Frailty Score) - Observational, Prospective, Singe Center Study Unknown status NCT02650388 Phase 4
36 A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Aptensio XR® in Children Ages 4 to Under 6 Years Diagnosed With Attention Deficit-Hyperactivity Disorder (ADHD) Unknown status NCT02683265 Phase 4 Aptensio XR;Placebo
37 Delirium: Is Prophylactic Drug Therapy Useful in High Risk Patients as Defined by the Delirium Risk Prediction Model? Unknown status NCT03199950 Phase 4 Haloperidol;Placebo Oral Tablet
38 Melatonin Use in the Intensive Care Elderly Population Unknown status NCT03013790 Phase 4 Melatonin
39 A Pilot Open Trial Of Ziprasidone, Early In The Course Of Pediatric Psychotic Illness Completed NCT00199940 Phase 4 Ziprasidone
40 An Open-labeled, Parallel-group, Single-blinded (Rater) Pilot Study to Investigate the Neuroprotective Effects of of Low-dose Lithium in Young Subjects at Ultra High Risk (UHR) of Developing a First-episode Psychotic Disorder Completed NCT00202306 Phase 4 lithium carbonate
41 Therapeutic Effect Between Quetiapine and Haloperidol on the Treatment of Methamphetamine - Induced Psychosis Completed NCT01939093 Phase 4 Diazepam;Stugeron
42 Efficacy and Safety of Paliperidone ER in Patients With First Episode Psychosis: an Open-label, Prospective Multi-center Study Completed NCT01157585 Phase 4 paliperidone ER
43 Efficacy and Safety With Ziprasidone in the Treatment of First-episode Schizophrenia Spectrum Disorder: Multi-center Study Completed NCT01157559 Phase 4 Ziprasidone
44 Efficacy and Safety of Aripiprazole in Patients With First Episode Psychosis: an Open-label, Prospective Multi-center Study Completed NCT01026584 Phase 4 Aripiprazole
45 The Cognitive Effects of Risperidone and Olanzapine Completed NCT00108368 Phase 4 Risperidone;Olanzapine
46 Treatment of Major Depressive Episodes During the Course of Psychotic Disorders With Duloxetine Completed NCT00224302 Phase 4 Duloxetine
47 An Open-Label Study of Aripiprazole to Evaluate the Safety and Tolerability in Patients With Psychosis Associated With Parkinson's Disease Completed NCT00095810 Phase 4 aripiprazole
48 A Multi-Center Study to Examine The Clinical Effects of Cross Titration of Antipsychotics With Ziprasidone in Subjects With Schizophrenia or Schizoaffective Disorder Completed NCT00137020 Phase 4 ziprasidone
49 Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI): A Pilot Study Completed NCT00453804 Phase 4 injectable naltrexone;oral naltrexone
50 Childhood Onset Psychotic Disorders: Characterization and Treatment With Atypical Neuroleptics Completed NCT00001656 Phase 4 Olanzapine;Clozapine

Search NIH Clinical Center for Psychotic Disorder

Inferred drug relations via UMLS 72 / NDF-RT 51 :


acetophenazine
Acetophenazine maleate
Aripiprazole
Carbamazepine
Chlorpromazine
Chlorpromazine hydrochloride
Chlorprothixene
Clozapine
CLOZAPINE (CARACO)
CLOZAPINE (CLOZARIL)
CLOZAPINE (IVAX)
CLOZAPINE (TEVA)
CLOZAPINE (VERSACLOZ)
Droperidol
Fazaclo
Fluphenazine
Fluphenazine
fluphenazine decanoate
Fluphenazine enanthate
Fluphenazine Hydrochloride
Haloperidol
Haloperidol
haloperidol decanoate
Haloperidol lactate
HYPERICUM PERFORATUM (ST. JOHN'S WORT)
Lorazepam
Loxapine
Loxapine hydrochloride
Loxapine Succinate
Mesoridazine
Mesoridazine besylate
Molindone
Molindone Hydrochloride
Mylan brand of clozapine
olanzapine
Olanzapine
Periciazine
Perphenazine
Pimozide
Prochlorperazine
Prochlorperazine Edisylate Salt
Prochlorperazine Maleate
Promazine
Promazine Hydrochloride
quetiapine
Quetiapine
Quetiapine fumarate
Reserpine
Risperidone
Thioridazine
Thioridazine
Thioridazine Hydrochloride
Thiothixene
Thiothixene hydrochloride
Trifluoperazine
Trifluoperazine
Trifluoperazine hydrochloride
Triflupromazine
Triflupromazine hydrochloride
UDL brand of clozapine
Ziprasidone

Genetic Tests for Psychotic Disorder

Anatomical Context for Psychotic Disorder

MalaCards organs/tissues related to Psychotic Disorder:

41
Brain, Testes, Eye, Cortex, Prefrontal Cortex, Pituitary, Heart

Publications for Psychotic Disorder

Articles related to Psychotic Disorder:

(show top 50) (show all 8198)
# Title Authors PMID Year
1
Bipolar and psychotic disorders in elite athletes: a narrative review. 38 17
31097458 2019
2
Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin. 17
31159608 2019
3
The influence of substance use on the effectiveness of antipsychotic medication: a prospective, pragmatic study. 17
31140342 2019
4
Alterations of the dopamine transporter in resting lymphocytes of patients with different psychotic disorders. 9 38
19910055 2010
5
Neuregulin 1-stimulated phosphorylation of AKT in psychotic disorders and its relationship with neurocognitive functions. 9 38
19524002 2009
6
Discontinued psychiatric drugs in 2008. 9 38
19715445 2009
7
Discovery and biological profile of isoindolinone derivatives as novel metabotropic glutamate receptor 1 antagonists: a potential treatment for psychotic disorders. 9 38
19692242 2009
8
Clozapine-induced obsessive-compulsive syndromes improve in combination with aripiprazole. 9 38
19644230 2009
9
Kynurenine pathway in psychosis: evidence of increased tryptophan degradation. 9 38
18562404 2009
10
Polymorphisms in SLC6A4, PAH, GABRB3, and MAOB and modification of psychotic disorder features. 9 38
19268543 2009
11
McLean-Harvard International First-Episode Project: two-year stability of DSM-IV diagnoses in 500 first-episode psychotic disorder patients. 9 38
19200422 2009
12
Association of a nonsynonymous variant of DAOA with visuospatial ability in a bipolar family sample. 9 38
18466879 2008
13
5-HT1A gene variants and psychiatric disorders: a review of current literature and selection of SNPs for future studies. 9 38
18047755 2008
14
Investigation of serum BDNF levels in drug-naive patients with schizophrenia. 9 38
18502013 2008
15
Catechol-O-methyltransferase Val158Met polymorphism and clinical characteristics in first episode non-affective psychosis. 9 38
18092319 2008
16
A dysbindin risk haplotype associated with less severe manic-type symptoms in psychosis. 9 38
18162312 2008
17
The dysbindin gene (DTNBP1) is associated with methamphetamine psychosis. 9 38
17555717 2008
18
Association analysis of exon III and exon I polymorphisms of the dopamine D4 receptor locus in Mexican psychotic patients. 9 38
17822780 2007
19
D-amino acid oxidase (DAO) genotype and mood symptomatology in schizophrenia. 9 38
17890006 2007
20
Association of distinct allelic haplotypes of DISC1 with psychotic and bipolar spectrum disorders and with underlying cognitive impairments. 9 38
17673452 2007
21
An association study between cathechol-O-methyltransferase gene and mental retardation in the Chinese Han population. 9 38
17442488 2007
22
Association between the DTNBP1 gene and intelligence: a case-control study in young patients with schizophrenia and related disorders and unaffected siblings. 9 38
17445278 2007
23
Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. 9 38
17355517 2007
24
Risk factors for the emergence of psychotic disorders in adolescents with 22q11.2 deletion syndrome. 9 38
17403981 2007
25
The child and adolescent first-episode psychosis study (CAFEPS): design and baseline results. 9 38
17267179 2007
26
Diagnostic stability over 3 years in a total group of first-episode psychosis patients. 9 38
17523030 2007
27
Dysregulation of tau phosphorylation is a hypothesized point of convergence in the pathogenesis of alzheimer's disease, frontotemporal dementia and schizophrenia with therapeutic implications. 9 38
16793187 2006
28
Risk factors for completed suicide in schizophrenia and other chronic psychotic disorders: a case-control study. 9 38
16626940 2006
29
Sensory gating deficits, pattern completion, and disturbed fronto-limbic balance, a model for description of hallucinations and delusions in schizophrenia. 9 38
16824690 2006
30
Common alterations in the serotonin transporter in platelets and lymphocytes of psychotic patients. 9 38
16453253 2006
31
COMT genetic variation confers risk for psychotic and affective disorders: a case control study. 9 38
16232322 2005
32
Hyperprolinemia is a risk factor for schizoaffective disorder. 9 38
15494707 2005
33
Linkage disequlibrium in the DTNBP1 (dysbindin) gene region and on chromosome 1p36 among psychotic patients from a genetic isolate in Israel: findings from identity by descent haplotype sharing analysis. 9 38
15211634 2004
34
Clinical features of psychotic disorders and polymorphisms in HT2A, DRD2, DRD4, SLC6A3 (DAT1), and BDNF: a family based association study. 9 38
14755448 2004
35
Decreased levels of dopamine D3 receptor mRNA in schizophrenic and bipolar patients. 9 38
15539862 2004
36
GAD(67): the link between the GABA-deficit hypothesis and the dopaminergic- and glutamatergic theories of psychosis. 9 38
12811640 2003
37
Premorbid functioning in early-onset psychotic disorders. 9 38
12921474 2003
38
[A case report of factitious disorder with hallucinations]. 9 38
14569475 2003
39
The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. 9 38
11910268 2002
40
Tryptophan hydroxylase gene and major psychoses. 9 38
11472792 2001
41
Children and adolescents with psychotic disorder not otherwise specified: a 2- to 8-year follow-up study. 9 38
11458307 2001
42
DRD4 exon 3 variants associated with delusional symptomatology in major psychoses: a study on 2,011 affected subjects. 9 38
11353451 2001
43
Dopamine D4 receptor (DRD4) gene polymorphism in the first psychotic episode. 9 38
11282178 2001
44
New neurochemical markers for psychosis: a working hypothesis of their operation. 9 38
11059795 2000
45
Clinical predictors of acute response with quetiapine in psychotic mood disorders. 9 38
10817103 2000
46
Clozapine treatment in a population of adults with mental retardation. 9 38
10695641 2000
47
Analysis of neuroleptic binding affinities and potencies for the different human D2 dopamine receptor missense variants. 9 38
10208638 1999
48
Elevated prolactin in pediatric patients on typical and atypical antipsychotics. 9 38
10630453 1999
49
5-Hydroxytryptamine-induced excitatory postsynaptic currents in neocortical layer V pyramidal cells: suppression by mu-opiate receptor activation. 9 38
9881863 1998
50
Twelve-nucleotide repeat polymorphism of D4 dopamine receptor gene in Chinese familial schizophrenic patients. 9 38
9532348 1998